Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.
JérômeLeGoff;
GérardGrésenguet;
ChrysostomeGody;
Jean De DieuLongo;
NzambiKhonde;
Helen A Weiss 
;
Philippe Mayaud ;
LaurentBélec;
ANRS 12-12 Study Group;
(2011)
Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.
Clinical and vaccine immunology, 18 (7).
pp. 1191-1193.
ISSN 1556-6811
DOI: 10.1128/CVI.05003-11
;
Philippe Mayaud ;
LaurentBélec;
ANRS 12-12 Study Group;
(2011)
Performance of the BioPlex 2200 multiplexing immunoassay platform for the detection of herpes simplex virus type 2 specific antibodies in African settings.
Clinical and vaccine immunology, 18 (7).
pp. 1191-1193.
ISSN 1556-6811
DOI: 10.1128/CVI.05003-11
The BioPlex platform was evaluated for the detection of herpes simplex virus 2 (HSV-2) antibodies in sub-Saharan Africa individuals in comparison to clinicovirological standards and compared to HerpeSelect. The sensitivities and specificities were, respectively, 88.9% and 93.5% for BioPlex and 89.9% and 92.7% for HerpeSelect. The agreement between both assays was 95.7%.
Full text not available from this repository.
Explore Further
Read more research from the creator(s):
Find work associated with the faculties and division(s):
Find work associated with the research centre(s):
Find work from this publication:
Find other related resources:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147317 (OA Location)
- 10.1128/CVI.05003-11 (DOI)
- 21562116 (PubMed)